Truist Defending Viking Therapeutics (VKTX): 'recommend investors take advantage of today’s selloff to add to shares'
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $120.00 price target on Viking Therapeutics (NASDAQ: VKTX)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
